Meeting
2021 ASCO Annual Meeting
Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.
Presenter
Ozgur Karakuzu, MSc, PhD
The University of Texas MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04171219
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2558)
DOI
10.1200/JCO.2021.39.15_suppl.2558
Abstract #
2558
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
Speaker: Hiroya Taniguchi, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
Speaker: Anthony W. Tolcher, MD, FASCO
Speaker: David F. McDermott, MD
Videos & Slides
2024 ASCO Annual Meeting
Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Speaker: Carlos Rojas, MD